Shared on27 Oct 25Fair value Decreased 1.23%
Novo Nordisk's analyst price target was slightly reduced to $438.59 from $444.05. Analysts pointed to moderated revenue growth and profitability expectations in their updated outlook.
Shared on26 Sep 25Fair value Decreased 3.27%
Novo Nordisk’s consensus analyst price target has been revised downward, primarily reflecting slightly softer revenue growth expectations, with the new fair value set at DKK444.05. What's in the News Novo Nordisk presented robust real-world and clinical data at major scientific congresses, highlighting significant cardiovascular, renal, weight loss, and liver benefits of its semaglutide-based therapies (Ozempic, Wegovy, Rybelsus) and the investigational agent cagrilintide, leading to new regulatory approvals and expanded indications for conditions such as type 2 diabetes, chronic kidney disease, cardiovascular disease, obesity, and MASH (Key Developments, August-September 2025).
Shared on11 Sep 25Fair value Decreased 1.34%
The modest downward revision in Novo Nordisk’s analyst price target reflects softer consensus revenue growth forecasts, with fair value decreasing slightly from DKK465.30 to DKK459.05. What's in the News Novo Nordisk received FDA approval for expanded indications for its leading semaglutide products: Wegovy® for treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis, and Ozempic® as the first and only medication approved for both glycemic control and renal/cardiovascular risk reduction in adults with type 2 diabetes and chronic kidney disease.
Shared on27 Aug 25Fair value Decreased 3.93%
Novo Nordisk's fair value estimate has been revised downward, primarily reflecting a modest decline in the company’s future P/E multiple, with the consensus analyst price target decreasing from DKK484.33 to DKK465.30. What's in the News Novo Nordisk continues to expand its GLP-1 portfolio, with FDA approvals for new indications: Ozempic® is now the first and only drug approved to treat both glycemic control and reduce cardiovascular and kidney risks in type 2 diabetes (T2D) with chronic kidney disease (CKD), while Wegovy® received the first-ever GLP-1 approval for metabolic dysfunction-associated steatohepatitis (MASH), showing significant improvements in fibrosis and resolution of steatohepatitis (Key Developments, Aug 15 & 19, 2025).
Shared on31 Jul 25Fair value Decreased 14%
Novo Nordisk's consensus analyst price target saw a minor decrease, with revenue growth and future P/E forecasts remaining essentially stable, resulting in a slight downward revision of fair value to DKK553.19. What's in the News Maziar Mike Doustdar has been appointed CEO, succeeding Lars Fruergaard Jørgensen, who steps down amid share price and market challenges.
Shared on23 Apr 25Fair value Decreased 0.93%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 4.91%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Decreased 1.77%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 2.02%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Increased 0.35%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Decreased 0.51%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on11 Mar 25Fair value Increased 25%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.